Brain, Vol. 126, No. 4, 814-826,
April 2003
© 2003 Guarantors of Brain
doi: 10.1093/brain/awg090
Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia
1 Garvan Institute of Medical Research, 2 Prince of Wales Medical Research Institute and the University of New South Wales, 3 Centre for Education and Research on Ageing, Concord Hospital and the University of Sydney, 4 Old Age Psychiatry, Prince of Wales Hospital, Sydney, 5 Department of Psychiatry, University of Newcastle and the Neuropsychiatry Service, Newcastle and 6 Sir James McCusker Alzheimer’s Disease Research Unit, Hollywood Private Hospital, Perth, AustraliaCorresponding author: A/Prof Glenda Halliday, Prince of Wales Medical Research Institute, Barker Street, Randwick, Sydney 2031, NSW, Australia E-mail: g.halliday{at}unsw.edu.au
The majority of cases with frontotemporal dementia (FTD) have no tau deposition in the brain, yet mutations in the tau gene lead to a similar clinical phenotype with insoluble tau depositing in neuropathological lesions. We report two tau gene mutations at positions +19 and +29, in the intronic sequences immediately following the stem loop structure in exon 10, which segregate with FTD. Exon-trapping experiments showed that these gene mutations alter the splicing out of exon 10 and produce an increase in tau isoforms with three microtubule binding domains (three repeat tau). Mutagenesis experiments demonstrated that the +19 mutation was responsible for the increase in three repeat tau, possibly by altering an intron silencer modulator sequence element found at this region of the gene. Microtubule binding experiments revealed a significant decrease in microtubule assembly with increasing amounts of three and decreasing amounts of four repeat tau. Brain autopsy was available in one case. Analysis of the type of soluble tau isoforms revealed an increase in three repeat tau and an absence of tau isoforms with exon 3 inserts. No insoluble tau was isolated in the tissue fractions, consistent with the absence of tau-positive histopathology. There was also an increase in tau degradation products suggestive of increased proteolysis. This increase in tau breakdown products was associated with TUNEL- and activated caspase-3-positive neurons identified histologically. These studies show that increases in soluble three repeat tau can be responsible for FTD in cases with tau gene mutations in the intronic region immediately adjacent to the stem loop in exon 10. These cases of FTD have tau isoforms (without exon 3 inserts) that do not form abnormal aggregates and appear more prone to proteolysis. The increase in tau proteolysis was associated with increased evidence of apoptosis. This mechanism of neurodegeneration may be more applicable to the majority of FTD cases, which do not accumulate insoluble tau deposits.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. S. Wolfe Tau Mutations in Neurodegenerative Diseases J. Biol. Chem., March 6, 2009; 284(10): 6021 - 6025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shi, T. Zhang, C. Zhou, M. O. Chohan, X. Gu, J. Wegiel, J. Zhou, Y.-W. Hwang, K. Iqbal, I. Grundke-Iqbal, et al. Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down Syndrome J. Biol. Chem., October 17, 2008; 283(42): 28660 - 28669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Goldman, J. Adamson, A. Karydas, B. L. Miller, and M. Hutton New Genes, New Dilemmas: FTLD Genetics and Its Implications for Families American Journal of Alzheimer's Disease and Other Dementias, January 1, 2008; 22(6): 507 - 515. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Goedert and M. G. Spillantini Frontotemporal lobar degeneration through loss of progranulin function. Brain, November 1, 2006; 129(Pt 11): 2808 - 2810. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Pickering-Brown, M. Baker, J. Gass, B. F. Boeve, C. T. Loy, W. S. Brooks, I. R. A. Mackenzie, R. N. Martins, J. B. J. Kwok, G. M. Halliday, et al. Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain, November 1, 2006; 129(Pt 11): 3124 - 3126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Halliday, Y. J. C. Song, H. Creasey, J. G. Morris, W. S. Brooks, and J. J. Kril Neuropathology in the S305S tau gene mutation. Brain, March 1, 2006; 129(Pt 3): E40 - E40. [Full Text] [PDF]
|
|
|
|
|
|
I. D'Souza and G. D. Schellenberg Arginine/Serine-rich Protein Interaction Domain-dependent Modulation of a Tau Exon 10 Splicing Enhancer: ALTERED INTERACTIONS AND MECHANISMS FOR FUNCTIONALLY ANTAGONISTIC FTDP-17 MUTATIONS {Delta}280K AND N279K J. Biol. Chem., February 3, 2006; 281(5): 2460 - 2469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Zarranz, I. Ferrer, E. Lezcano, M. I. Forcadas, B. Eizaguirre, B. Atares, B. Puig, J. C. Gomez-Esteban, C. Fernandez-Maiztegui, I. Rouco, et al. A novel mutation (K317M) in the MAPT gene causes FTDP and motor neuron disease Neurology, May 10, 2005; 64(9): 1578 - 1585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, J. Wang, L. Gao, R. Lafyatis, S. Stamm, and A. Andreadis Tau Exons 2 and 10, Which Are Misregulated in Neurodegenerative Diseases, Are Partly Regulated by Silencers Which Bind a SRp30c{middle dot}SRp55 Complex That Either Recruits or Antagonizes htra2{beta}1 J. Biol. Chem., April 8, 2005; 280(14): 14230 - 14239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jiang, A. Mankodi, M. S. Swanson, R. T. Moxley, and C. A. Thornton Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons Hum. Mol. Genet., December 15, 2004; 13(24): 3079 - 3088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O Piguet, W S Brooks, G M Halliday, P R Schofield, P M Stanford, J B J Kwok, M-G Spillantini, D Yancopoulou, P J Nestor, G A Broe, et al. Similar early clinical presentations in familial and non-familial frontotemporal dementia J. Neurol. Neurosurg. Psychiatry, December 1, 2004; 75(12): 1743 - 1745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Hernandez, M. Perez, J. J. Lucas, A. M. Mata, R. Bhat, and J. Avila Glycogen Synthase Kinase-3 Plays a Crucial Role in Tau Exon 10 Splicing and Intranuclear Distribution of SC35: IMPLICATIONS FOR ALZHEIMER'S DISEASE J. Biol. Chem., January 30, 2004; 279(5): 3801 - 3806. [Abstract] [Full Text] [PDF]
|
|